SEC Comment Letter for Aptose Biosciences Inc. (CIK 0000882361) (APTOF) — Apr 12, 2019
Aptose Biosciences Inc. (CIK 0000882361)
Date: April 12, 2019 · CIK: 0000882361 · Accession: 0000000000-19-007086
AI Filing Summary & Sentiment
File numbers found in text: 001-32001
Letter
April 12, 2019 Gregory Chow Senior Vice President and Chief Financial Officer Aptose Biosciences Inc. 251 Consumers Road, Suite 1105 Toronto, Ontario, Canada M2J 4R3 Re:Aptose Biosciences Inc. Form 10-K for the Fiscal Year Ended December 31, 2018 Filed March 12, 2019 File No. 001-32001 Dear Mr. Chow: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance
Show Raw Text
April 12, 2019
Gregory Chow
Senior Vice President and Chief Financial Officer
Aptose Biosciences Inc.
251 Consumers Road, Suite 1105
Toronto, Ontario, Canada M2J 4R3
Re:Aptose Biosciences Inc.
Form 10-K for the Fiscal Year Ended December 31, 2018
Filed March 12, 2019
File No. 001-32001
Dear Mr. Chow:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance